Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135683 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1STAT3GAAALDH1A1 | |
| SCHEMBL4849121 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2STAT3GAAALDH1A1MEN1 | |
| SCHEMBL3138941 | 0.80 | SLC22A12 (0.44) | NPC1STAT3GAAALDH1A1RAB9A | |
| SCHEMBL3135536 | 0.79 | CTSD (0.53) | SMN1; SMN2NPC1GAAABCB1ROCK2 | |
| SCHEMBL3138802 | 0.78 | FYN (0.44) | SMN1; SMN2STAT3GAAALDH1A1MEN1 | |
| SCHEMBL3139236 | 0.77 | CHEK1 (0.51) | GAAABCB1ROCK2ROCK1TNFRSF1A | |
| SCHEMBL15026732 | 0.77 | GAA (0.47) | SMN1; SMN2NPC1GAAALDH1A1MEN1 | |
| SCHEMBL3138697 | 0.76 | ALDH1A1 (0.54) | SMN1; SMN2NPC1ALDH1A1ABCB1TNFRSF1A | |
| SCHEMBL15741815 | 0.76 | RAB9A (0.53) | SMN1; SMN2NPC1STAT3GAAALDH1A1 | |
| SCHEMBL805306 | 0.75 | CES2 (0.46) | SMN1; SMN2NPC1STAT3GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | SMN1; SMN2 3807/4885NPC1 247/4885STAT3 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.